Korro Bio, Inc.
4.90%
706,556
1703647
Jun 23, 2026
Aug 4, 2026, 05:13 PM
Reporting Persons (6)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Atlas Venture Fund XI, L.P. | Partnership | 4.90% | 706,556 | 0 | 706,556 |
| Atlas Venture Associates XI, L.P. | Partnership | 4.90% | 706,556 | 0 | 706,556 |
| Atlas Venture Associates XI, LLC | Other | 4.90% | 706,556 | 0 | 706,556 |
| Atlas Venture Opportunity Fund II, L.P. | Partnership | 1.00% | 146,305 | 0 | 146,305 |
| Atlas Venture Associates Opportunity II, L.P. | Partnership | 1.00% | 146,305 | 0 | 146,305 |
| Atlas Venture Associates Opportunity II, LLC | Other | 1.00% | 146,305 | 0 | 146,305 |
Disclosure Items (3)
Common Stock, par value $0.001 per share
Korro Bio, Inc.
60 First Street, 2nd Floor, Suite 250, Cambridge, MA, 02141
As of the date hereof, Atlas XI is the record owner of 706,556 shares of Common Stock. AVA XI LP is the general partner of Atlas XI and AVA XI LLC is the general partner of AVA XI LP. Each of Atlas XI, AVA XI LP and AVA XI LLC has shared voting and dispositive power over the shares held by Atlas XI. As such, each of Atlas XI, AVA XI LP and AVA XI LLC may be deemed to beneficially own the shares held by Atlas XI. As of the date hereof, AVOF II is the record owner of 146,305 shares of Common Stock. AVAO II LP is the general partner of AVOF II and AVAO II LLC is the general partner of AVAO II LP. Each of AVOF II, AVAO II LP and AVAO II LLC has shared voting and dispositive power over the shares held by AVOF II. As such, each of AVOF II, AVAO II LP and AVAO II LLC may be deemed to beneficially own the shares held by AVOF II. Each of the Fund XI Reporting Persons and the Opportunity Fund II Reporting Persons may be deemed to beneficially own 4.9% and 1.0%, respectively, of the Issuer's outstanding Common Stock, which percentages are calculated based upon 14,422,571 shares of Common Stock outstanding as of May 4, 2026, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 7, 2026. Collectively, the Reporting Persons beneficially own an aggregate of 852,861 shares of Common Stock, which represents an estimated 5.9% of the Issuer's outstanding Common Stock. The Fund XI Reporting Persons and the Opportunity Fund II Reporting Persons are under common control and as a result, the Reporting Persons may be deemed to be members of a group. However, the Reporting Persons disclaim such group membership, and this Schedule 13D shall not be deemed an admission that the Reporting Persons are members of a group for purposes of Section 13 or for any other purposes.
Each of Atlas XI, AVA XI LP and AVA XI LLC has shared voting and dispositive power over 706,556 shares held by Atlas XI. Each of AVOF II, AVAO II LP and AVAO II LLC has shared voting and dispositive power over 146,305 shares held by AVOF II.
The transactions in the common stock by the Reporting Persons subsequent to the date that is sixty days prior to the date of the triggering of this filing are set forth in Exhibit 99.2 and are incorporated herein by reference.
No other person is known by the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock beneficially owned by the Reporting Persons.
Not applicable.
99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to the Reporting Persons' Schedule 13D, filed with the SEC on November 13, 2023). 99.2 Transactions in Common Stock During the Past Sixty Days